Reprint

Plasma in Cancer Treatment

Edited by
May 2021
358 pages
  • ISBN978-3-0365-1209-9 (Hardback)
  • ISBN978-3-0365-1208-2 (PDF)

This book is a reprint of the Special Issue Plasma in Cancer Treatment that was published in

Biology & Life Sciences
Medicine & Pharmacology
Summary
In the last decade, research on cold atmospheric plasma (CAP) has significantly advanced our understanding of the effect of CAP on cancer cells and their potential for cancer treatment. This effect is due to the reactive oxygen and nitrogen species (RONS) created by plasma. This has been demonstrated for different cancer cell lines and the first clinical trials showed promising results. In addition, plasma could be combined with other treatments—such as immunotherapy—to boost its anticancer activity. The addition of new research tools to study the response of cancer cells to CAP—such as 3D in vitro, in ovo, and in vivo models and in silico approaches—as well as the use of -OMICS technologies could aid in unravelling the underlying mechanisms of CAP in cancer treatment. In order to progress towards widespread clinical application of CAP, an integrated study of the multidimensional effect of CAP in cancer treatment is essential. In this book, reviews and original research papers are published that provide new insights into the mechanisms of cold atmospheric plasma in cancer treatment, based on in vitro and in vivo experiments, clinical studies, as well as computer modeling.
Format
  • Hardback
License
© by the authors
Keywords
cell adhesion; plasma medicine; oncology; cold atmospheric plasma; selectivity; plasma-treated liquid; dielectric barrier discharge; pancreatic cancer; pancreatic stellate cells; cold atmospheric plasma; immunogenic cell death; dendritic cells; cold atmospheric plasma; cell communication; extracellular matrix (ECM); reactive oxygen and nitrogen species (ROS); tumour microenvironment (TME); extracellular vesicles; communication junctions; three-dimensional in vitro culture models; apoptosis; cold atmospheric plasma; breast cancer; genome-wide expression; reactive oxygen species; anticancer drugs; pancreatic cancer; screening; tumor spheroids; anticancer drugs; combination therapy; kINPen; plasma medicine; reactive oxygen and nitrogen species; ROS; cancer; non-thermal atmospheric pressure plasma (NTP); plasma medicine; indirect treatment; plasma-treated phosphate-buffered saline; electroporation; electric pulses; pulsed electric field amplitude; melanoma; long-lived reactive species; bone cancer; osteosarcoma; cold atmospheric plasma; reactive species; plasma-activated liquid; Ringer’s saline; organotypic model; nonthermal biocompatible plasma; soft jet plasma; reactive oxygen and nitrogen species; human glioblastoma; p38/MAPK pathway; tissue penetration; non-thermal plasma; non-invasive plasma treatment (NIPP); cervical intraepithelial neoplasia (CIN); Raman imaging; Raman microspectroscopy; Plasma lipid interactions; cold physical plasma; plasma medicine; reactive oxygen and nitrogen species; radiation therapy; non-thermal plasma; radio-frequency discharge; breast cancer; PARP-inhibitor; olaparib; DNA-damage; gold quantum dots; plasma; cancer; nanomaterials; cellular uptake; invasiveness; cold atmospheric pressure plasma; plasma medicine; plasma-activated Ringer’s lactate solution; ovarian cancer; cytotoxicity; selectivity; cancer; plasma-activated liquids; multicellular tumor spheroids; long-lived reactive oxygen and nitrogen species; non-thermal plasma; high frequency electrosurgery; plasma treatment; cold atmospheric plasma (CAP); free radicals; reactive species; cancer selectivity; cervical cancer treatment; cervical intraepithelial neoplasia; cholangiocarcinoma; cold plasma; innovative therapy; tumor cells; macrophages; plasma selectivity; plasma jet; n/a